Short Interest in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Increases By 407.4%

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIOGet Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 20,657 shares, an increase of 407.4% from the March 31st total of 4,071 shares. Based on an average daily volume of 27,055 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.8% of the company’s shares are short sold.

ALPS Medical Breakthroughs ETF Price Performance

Shares of NYSEARCA:SBIO opened at $54.41 on Friday. ALPS Medical Breakthroughs ETF has a 52-week low of $26.86 and a 52-week high of $57.77. The business’s 50 day moving average is $52.05 and its 200 day moving average is $49.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SBIO. Jones Financial Companies Lllp bought a new position in ALPS Medical Breakthroughs ETF in the first quarter worth approximately $782,000. Raymond James Financial Inc. bought a new position in ALPS Medical Breakthroughs ETF in the second quarter worth approximately $82,000. Moran Wealth Management LLC grew its stake in ALPS Medical Breakthroughs ETF by 72.2% in the third quarter. Moran Wealth Management LLC now owns 17,187 shares of the company’s stock worth $668,000 after purchasing an additional 7,206 shares in the last quarter. Sterling Investment Advisors Ltd. bought a new position in ALPS Medical Breakthroughs ETF in the third quarter worth approximately $315,000. Finally, Comerica Bank purchased a new stake in ALPS Medical Breakthroughs ETF during the third quarter worth $27,000.

About ALPS Medical Breakthroughs ETF

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.

Further Reading

Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.